Development of a Novel 18 F‐Labeled Radioligand for Imaging Translocator Protein With Positron Emission Tomography
iRADIOLOGY · 2026-06 · 4 (3) · 261-272
DOI: 10.1002/ird3.70081 ↗Kurz gefasst
Fachartikel in der Zeitschrift iRADIOLOGY, online erschienen am 15.06.2026. Verfasst von Jian Rong und 8 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Translocator protein 18 kDa (TSPO) is a well‐established biomarker of neuroinflammation and is implicated in the pathophysiology of various neurodegenerative diseases, including Alzheimer's disease (AD). Despite existing radioligands, there remains a critical need for novel TSPO‐targeted positron emission tomography (PET) tracers with improved binding specificity, higher brain uptake, and favorable pharmacokinetics.
Methods
We designed and synthesized a class of novel TSPO ligand candidates. Following in vitro binding affinity screening, the lead Compound 3 (TSPO‐1118) was radiolabeled with fluorine‐18. [ 18 F] 3 ([ 18 F]TSPO‐1118) was evaluated in two transgenic AD mouse models (3xTg and APP/PS1) and compared to age‐matched wild‐type (WT) controls. Biodistribution and radiometabolite analyses were conducted in CD‐1 mice to assess brain penetration and metabolic stability.
Results
Compound 3 (TSPO‐1118) demonstrated superior binding affinity for TSPO ( K i = 2.3 nM), outperforming both other analogs in the series and the benchmark tracer GE180. [ 18 F] 3 ([ 18 F]TSPO‐1118) exhibited significantly higher brain uptake in both 3xTg and APP/PS1 mice relative to WT controls, including the cortex, thalamus, cerebellum, and hippocampus ( p < 0.05 to < 0.01, Student's two‐tailed t ‐test), consistent with elevated TSPO expression in disease models. The tracer also displayed favorable brain kinetics, high specific binding, and metabolic stability in vivo. Conclusions [ 18 F] 3 ([ 18 F]TSPO‐1118) represents a promising next‐generation PET radioligand for imaging TSPO with high affinity, robust brain uptake, and specificity in preclinical models of neurodegeneration. Its favorable profile supports further translational development toward clinical application in neuroinflammatory and neurodegenerative disorders.
Zitieren
APA
Rong, J., Zhao, C., Zhou, X., Chen, J., Gao, Y., Song, Z., Li, Y., Li, Z., & Liang, S. H. (2026). Development of a Novel 18 F‐Labeled Radioligand for Imaging Translocator Protein With Positron Emission Tomography. iRADIOLOGY, 4(3), 261-272. https://doi.org/10.1002/ird3.70081
Vancouver
Rong J, Zhao C, Zhou X, Chen J, Gao Y, Song Z, et al. Development of a Novel 18 F‐Labeled Radioligand for Imaging Translocator Protein With Positron Emission Tomography. iRADIOLOGY. 2026;4(3):261-272. doi:10.1002/ird3.70081
BibTeX
@article{Rong2026,
author = {Rong, Jian and Zhao, Chunyu and Zhou, Xin and Chen, Jiahui and Gao, Yabiao and Song, Zhendong and Li, Yinlong and Li, Zijing and Liang, Steven H.},
title = {Development of a Novel 18 F‐Labeled Radioligand for Imaging Translocator Protein With Positron Emission Tomography},
journal = {iRADIOLOGY},
year = {2026},
volume = {4},
number = {3},
pages = {261--272},
doi = {10.1002/ird3.70081}
}
EUVIMED